Request Demo
Recent blog posts
Latest Hotspot
8 min read
CTR20261026 Human normal immunoglobulin(Guangdong Shuanglin Biological Pharmaceutical ) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20261026 clinical trial report covering Human normal immunoglobulin(Guangdong Shuanglin Biological Pharmaceutical ), Phase 3, endpoints, sponsor, geogra
Latest Hotspot
8 min read
NCT07494409 AND-017 Anemia in chronic kidney disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07494409 clinical trial report covering AND-017, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07498634 Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) Ankylosing Spondylitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07498634 clinical trial report covering Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group), Phase 3, endpoints, sponsor, geograp
Latest Hotspot
8 min read
NCT07495852 Travoprost Glaucoma, Open-Angle Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07495852 clinical trial report covering Travoprost, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496736 Oseltamivir Phosphate Influenza, Human Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07496736 clinical trial report covering Oseltamivir Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496450 mRNA-1018 Influenza, Human Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07496450 clinical trial report covering mRNA-1018, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497438 Etoposide Lymphohistiocytosis, Hemophagocytic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07497438 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07495033 Telitacicept Interstitial lung disease due to connective tissue disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07495033 clinical trial report covering Telitacicept, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
TCTR20260327002 Tranexamic Acid Melanosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
TCTR20260327002 clinical trial report covering Tranexamic Acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496372 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07496372 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 3, endpoints, sponsor, geography, readout timing and
Latest Hotspot
8 min read
NCT07498426 NI-O752 Supranuclear Palsy, Progressive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07498426 clinical trial report covering NI-O752, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07498335 Atrasentan Hydrochloride Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07498335 clinical trial report covering Atrasentan Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.